29C1 Stock Chart & Stats
€1.93
€0.08(3.85%)
At close: 4:00 PM EDT
€1.93
€0.08(3.85%)
Day’s Range― - ―
52-Week Range€1.89 - €2.46
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€125.98M
Enterprise Value€291.62
Total Cash (Recent Filing)€10.05M
Total Debt (Recent Filing)€76.33M
Price to Earnings (P/E)7.5
Beta0.17
Next Earnings
Nov 11, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.42
Shares Outstanding63,514,038
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)2.19
Price to Sales (P/S)0.65
P/FCF Ratio10.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.95Price Target Upside52.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.07
Revenue Forecast (FY)€238.26M
Bulls Say, Bears Say
Bulls Say
Return To Profitability And Cash GenerationThe return to profitability, combined with positive operating and free cash flow, indicates that CareRx’s core pharmacy platform is converting revenue into internal funding. This supports reinvestment, debt service and shareholder returns while improving resilience over the next several quarters.
Long-term 3,000-bed Contract WinAdding approximately 3,000 retirement beds through a long-term national operator agreement should expand recurring prescription volumes and deepen institutional relationships. The expected contribution in Q4 provides a visible growth driver, while the stated margin profile supports scalable earnings expansion.
Operational Efficiency And Centralized FulfillmentCentralizing service beds into a fulfillment hub can improve pharmacy utilization and operating efficiency across the network. These actions may strengthen the economics of CareRx’s recurring institutional model by reducing duplication and supporting margin improvement as serviced-bed volumes grow.
Bears Say
Thin Operating MarginsAlthough CareRx is profitable, its relatively thin EBIT and EBITDA margins leave limited protection if costs rise or volumes soften. The modest operating cushion can make earnings more sensitive to reimbursement, funding and execution changes, constraining durable cash-flow flexibility.
Ontario Ward-bed Funding HeadwindThe Ontario ward-bed funding change creates a structural revenue headwind rather than a brief quarterly fluctuation, because management does not expect full recovery until late 2027. This weighs on near-term earnings and delays the return of affected revenue from existing care capacity.
Lower Cash And Higher Net DebtThe decline in cash alongside higher net debt reduces financial flexibility even though leverage remains moderate. Less liquidity leaves CareRx with a smaller buffer for capex, debt repayment or operating volatility, particularly while margins are thin and the Ontario funding impact persists.
CareRx News
29C1 FAQ
What was CareRx’s price range in the past 12 months?
CareRx lowest stock price was €1.89 and its highest was €2.46 in the past 12 months.
What is CareRx’s market cap?
CareRx’s market cap is €125.98M.
When is CareRx’s upcoming earnings report date?
CareRx’s upcoming earnings report date is Nov 11, 2026 which is in 43 days.
How were CareRx’s earnings last quarter?
CareRx released its earnings results on Jul 29, 2026. The company reported €0.006 earnings per share for the quarter, missing the consensus estimate of €0.014 by -€0.008.
Is CareRx overvalued?
According to Wall Street analysts CareRx’s price is currently Undervalued.
Does CareRx pay dividends?
CareRx does not currently pay dividends.
What is CareRx’s EPS estimate?
CareRx’s EPS estimate is 0.02.
How many shares outstanding does CareRx have?
CareRx has 63,514,038 shares outstanding.
What happened to CareRx’s price movement after its last earnings report?
CareRx reported an EPS of €0.006 in its last earnings report, missing expectations of €0.014. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of CareRx?
Currently, no hedge funds are holding shares in DE:29C1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CareRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€2.95 (52.70% Upside)
€2.95 (52.70% Upside)
Insider Transactions
Bought Shares
Worth €19.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.47%
12-Months-Change
Fundamentals
Return on Equity
2.59%
Trailing 12-Months
Asset Growth
11.38%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CareRx
CareRx Corporation, operating with its subsidiaries, specializes in delivering tailored pharmaceutical services to Canada's senior demographic. The company manages a vast network of medication dispensing facilities, which are responsible for providing chronic prescriptions and a variety of other advanced clinical pharmacy solutions. Currently, it caters to approximately 50,000 individuals residing in roughly 900 distinct senior and communal living environments, including extended care residences, retirement communities, supportive living facilities, and group homes. Founded in 2001 and based in Toronto, Canada, the corporation rebranded as CareRx Corporation in June 2020, having formerly been known as Centric Health Corporation.
29C1 Stock 12 Month Forecast
Average Price Target
€2.95
▲(52.70% Upside)
Technical Analysis
Extendicare
―
Nova Leap Health
―
Sienna Senior Living
―
Medical Facilities
―
WELL Health Technologies Corp
―